665. Lower Indeterminate Rates and Resolution by Retesting Using a Single Lithium-Heparin Tube Blood Collection Method for the QuantiFERON®-TB Gold Plus (QFT®-Plus)
Abstract Background The QuantiFERON-TB Gold Plus (QFT-Plus) test is an assay for detecting a cell-mediated immune response to M. tuberculosis (MTB). The assay measures the in vitro quantitative IFN-γ responses to MTB or control antigens in an incubated blood sample. There are 2 options for QFT-Plus blood collection. One option is a lithium-heparin transport tube with sample aliquots subsequently transferred to 4 QFT-Plus Blood Collection Tubes (1-tube QFT-Plus); the 2nd option is to directly collect the blood sample in 4 QFT-Plus collection tubes (4-tube QFT-Plus). In this study, we compared the indeterminate (IND) rates by the 2 blood collection methods to assess which method was superior. Methods For both blood collection methods, QFT-Plus ELISA testing was performed at various Quest Diagnostics sites as specified in the assay’s package insert. A retrospective data analysis of results for the above 2 blood processing methods was conducted. Also, we evaluated the rates of IND results in follow up blood collections. Statistical analyses were performed by the proportion test. Results In 2019, the IND result rate for greater than an 1.8 million 1-tube QFT-Plus draws was less than 1% whereas, the IND result rate for 0.3 million 4-tube draws was 4% This difference was significant. The overall MTB positive rate was 7% for the 1-tube method and 6% for the 4-tube method. Within a one-month interval following an initial blood collection event, 464 patients with an original IND result had a 2nd blood sample collected and tested. Only 35% of the 2nd blood collection events produced an IND result, with 52% of the 2nd sample results reporting as negative and 13% were positive. Conclusion This study found that the 1-tube QFT-Plus collection method reduces the IND rates by 4-fold compared to the observed rate in the 4-tube process. Additionally, two thirds of patients with an initial IND result resolved to either a positive or a negative result when retested within 1 month. Disclosures All Authors: No reported disclosures